stoxline Quote Chart Rank Option Currency Glossary
Bellerophon Therapeutics, Inc. (BLPH)
0.0571  -0.005 (-8.64%)    06-21 11:21
Open: 0.062
High: 0.062
Volume: 113,952
Pre. Close: 0.0625
Low: 0.0571
Market Cap: 1(M)
Technical analysis
2024-06-21 4:51:00 PM
Short term     
Mid term     
Targets 6-month :  0.07 1-year :  0.08
Resists First :  0.06 Second :  0.07
Pivot price 0.06
Supports First :  0.05 Second :  0.04
MAs MA(5) :  0.05 MA(20) :  0.05
MA(100) :  0.05 MA(250) :  0.18
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  24.3 D(3) :  27.1
RSI RSI(14): 47.9
52-week High :  0.75 Low :  0.02
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ BLPH ] has closed above bottom band by 33.6%. Bollinger Bands are 67.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.06 - 0.06 0.06 - 0.06
Low: 0.06 - 0.06 0.06 - 0.06
Close: 0.06 - 0.06 0.06 - 0.06
Company Description

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Headline News

Fri, 21 Jun 2024
Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size - Yahoo New Zealand News

Mon, 17 Jun 2024
Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated at - Defense World

Tue, 04 Jun 2024
option delistings on June 3rd - - TipRanks

Mon, 04 Mar 2024
Bellerophon Shareholders Vote to Dissolve Amid Board Resignations - - TipRanks

Tue, 25 Jul 2023
Why Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today? - InvestorPlace

Thu, 06 Jul 2023
Bellerophon Therapeutics (BLPH) Dips More Than Broader Markets: What You Should Know - Yahoo New Zealand News

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 12 (M)
Shares Float 10 (M)
Held by Insiders 15 (%)
Held by Institutions 8.7 (%)
Shares Short 90 (K)
Shares Short P.Month 124 (K)
Stock Financials
EPS -0.89
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.3
Profit Margin -164.1 %
Operating Margin -195.8 %
Return on Assets (ttm) -78.5 %
Return on Equity (ttm) -166 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.46
EBITDA (p.s.) -0.91
Qtrly Earnings Growth 0 %
Operating Cash Flow -12 (M)
Levered Free Cash Flow -10 (M)
Stock Valuations
PE Ratio -0.07
PEG Ratio 0
Price to Book value 0.19
Price to Sales 0.12
Price to Cash Flow -0.06
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android